BCL-2 inhibitor

This page covers all BCL-2 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting BCL-2, Bcl-2.

Targets

BCL-2 · Bcl-2

Marketed (3)

• Rd · Ascentage Pharma Group Inc. · Oncology
  Rd is a BCL-2 family protein inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.
• Venetoclax (VEN) · Nanfang Hospital, Southern Medical University · Oncology
  Venetoclax is a selective BCL-2 inhibitor that promotes apoptosis by blocking the anti-apoptotic protein BCL-2 in cancer cells.
• VEN · Janssen Research & Development, LLC · Oncology
  Venetoclax is a selective inhibitor of the anti-apoptotic protein BCL-2 that promotes cancer cell death by restoring apoptosis.

Phase 3 pipeline (4)

• Venetoclax 400 · Stichting Hemato-Oncologie voor Volwassenen Nederland · Oncology
  Venetoclax is a small molecule inhibitor of the BCL-2 protein, which is involved in apoptosis regulation.
• ARM A: Active Comparator Drug · Grupo Argentino de Tratamiento de la Leucemia Aguda · Oncology
  This drug works by inhibiting the BCL-2 protein, preventing cancer cell survival.
• Venetoclax-Decitabine/Azacitidine-Aclarubicin Association · The First Affiliated Hospital with Nanjing Medical University · Oncology
  Venetoclax targets and inhibits BCL-2, a protein that prevents apoptosis, while Decitabine/Azacitidine-Aclarubicin combination works by inducing DNA hypomethylation and promoting apoptosis in cancer cells.
• BGB-A445 · BeiGene · Oncology
  BGB-A445 is a Bcl-2 inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.

Phase 2 pipeline (3)

• ABL-101 · NHS Greater Glasgow and Clyde · Oncology
  ABL-101 is a small molecule inhibitor of the BCL-2 family.
• Induction Venetoclax · PrECOG, LLC. · Oncology
  BCL-2 inhibitor
• APG-115 · Ascentage Pharma Group Inc. · Oncology
  APG-115 is a small molecule inhibitor of BCL-2 family proteins.